Status:

COMPLETED

Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors

Lead Sponsor:

Fred Hutchinson Cancer Center

Collaborating Sponsors:

Livestrong Foundation

National Cancer Institute (NCI)

Conditions:

Breast Carcinoma

Cancer Survivor

Eligibility:

All Genders

18-39 years

Phase:

NA

Brief Summary

This randomized clinical trial studies survivorship care in reducing symptoms in young adult cancer survivors. Survivorship care programs that identify the needs of young adult cancer survivors and wa...

Detailed Description

PRIMARY OBJECTIVES: I. To test the impact of providing the essential elements of survivorship care on survivorship outcomes as indicated by reduction in symptoms (pain, fatigue, sleep disturbance, de...

Eligibility Criteria

Inclusion

  • Patients enrolled on phase 1 of the study are eligible (and/or if recruited from tumor registry or clinic follow-up schedules)
  • Diagnosed with invasive malignancy including: breast, gastrointestinal track, female or male genitourinary system, sarcoma of bone or soft-tissue, leukemia and lymphoma
  • Treated at one of the Survivorship Centers of Excellence or their community affiliates
  • Received a therapeutic intervention with at least one of the following modalities: surgery, cytotoxic chemotherapy, biological or targeted agents, radiation therapy (any modality)
  • Currently between 1.0 and 4.99 years from the completion of active cancer-directed therapy (cytotoxic chemotherapy, radiation therapy and/or definitive surgical intervention)
  • Patient must still be in active follow-up: seen for a follow-up visit in the participating center at least once in the 3 years prior to enrollment and/or scheduled to be seen for follow-up in the next 6 months (i.e. in active follow-up)
  • May be receiving "maintenance" therapy that has a goal of prevention of recurrence but there should be no expectations for further active treatment
  • Able to read and speak English adequate to complete the patient-reported outcomes (PRO) assessment

Exclusion

  • Prior visit to a survivorship clinic or previously provided with a treatment summary and care plan

Key Trial Info

Start Date :

August 3 2015

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2019

Estimated Enrollment :

390 Patients enrolled

Trial Details

Trial ID

NCT02192333

Start Date

August 3 2015

End Date

December 31 2019

Last Update

October 9 2020

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, United States, 90095

2

University of Colorado Cancer Center - Anschutz Cancer Pavilion

Aurora, Colorado, United States, 80045

3

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215

4

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, United States, 27599